SG10201703707YA - Pharmaceutical formulation containing improved antibody molecules - Google Patents

Pharmaceutical formulation containing improved antibody molecules

Info

Publication number
SG10201703707YA
SG10201703707YA SG10201703707YA SG10201703707YA SG10201703707YA SG 10201703707Y A SG10201703707Y A SG 10201703707YA SG 10201703707Y A SG10201703707Y A SG 10201703707YA SG 10201703707Y A SG10201703707Y A SG 10201703707YA SG 10201703707Y A SG10201703707Y A SG 10201703707YA
Authority
SG
Singapore
Prior art keywords
pharmaceutical formulation
antibody molecules
formulation containing
improved antibody
containing improved
Prior art date
Application number
SG10201703707YA
Inventor
Tomoyuki Igawa
Shinya Ishii
Atsuhiko Maeda
Mika Sakurai
Tetsuo Kojima
Tatsuhiko Tachibana
Hirotake Shiraiwa
Hiroyuki Tsunoda
Yoshinobu Higuchi
Chifumi Moriyama
Akira Hayasaka
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of SG10201703707YA publication Critical patent/SG10201703707YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
SG10201703707YA 2009-03-19 2010-03-19 Pharmaceutical formulation containing improved antibody molecules SG10201703707YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009069095 2009-03-19

Publications (1)

Publication Number Publication Date
SG10201703707YA true SG10201703707YA (en) 2017-06-29

Family

ID=42739479

Family Applications (3)

Application Number Title Priority Date Filing Date
SG2011066768A SG174428A1 (en) 2009-03-19 2010-03-19 Pharmaceutical formulation containing improved antibody molecules
SG10201900451SA SG10201900451SA (en) 2009-03-19 2010-03-19 Pharmaceutical formulation containing improved antibody molecules
SG10201703707YA SG10201703707YA (en) 2009-03-19 2010-03-19 Pharmaceutical formulation containing improved antibody molecules

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG2011066768A SG174428A1 (en) 2009-03-19 2010-03-19 Pharmaceutical formulation containing improved antibody molecules
SG10201900451SA SG10201900451SA (en) 2009-03-19 2010-03-19 Pharmaceutical formulation containing improved antibody molecules

Country Status (8)

Country Link
JP (2) JP4885308B2 (en)
KR (1) KR101468271B1 (en)
AR (1) AR075908A1 (en)
AU (1) AU2010225951B2 (en)
RU (1) RU2565809C2 (en)
SG (3) SG174428A1 (en)
TW (1) TWI440470B (en)
WO (1) WO2010106812A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN10515A (en) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
CA2700701C (en) 2007-09-26 2020-12-29 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
SG189775A1 (en) 2008-04-11 2013-05-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JO3417B1 (en) * 2010-01-08 2019-10-20 Regeneron Pharma Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
TWI505838B (en) 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody
CN102844332B (en) 2010-03-11 2015-08-19 瑞纳神经科学公司 The antibody combined in pH dependence antigen
US8580264B2 (en) * 2010-11-08 2013-11-12 Genentech, Inc. Subcutaneously administered anti-IL-6 receptor antibody
CN103328632A (en) 2010-11-30 2013-09-25 中外制药株式会社 Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
JP6043629B2 (en) * 2011-01-07 2016-12-14 中外製薬株式会社 Methods for improving antibody physical properties
SG192945A1 (en) 2011-02-25 2013-09-30 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc antibody
WO2012132067A1 (en) * 2011-03-30 2012-10-04 中外製薬株式会社 Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
UY34105A (en) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd STABLE LIQUID FORMULATION OF ETANERCEPT
EP3939996A1 (en) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (en) 2011-10-11 2017-07-01 再生元醫藥公司 Compositions for the treatment of rheumatoid arthritis and methods of using same
RU2739792C1 (en) 2011-11-30 2020-12-28 Чугаи Сейяку Кабусики Кайся Carrier containing a drug into a cell for forming an immune complex
WO2014163101A1 (en) 2013-04-02 2014-10-09 中外製薬株式会社 Fc region variant
EP3082861A1 (en) * 2013-12-20 2016-10-26 DioGenix Inc. Methods for evaluating neurological disease
JP6722455B2 (en) 2013-12-27 2020-07-15 中外製薬株式会社 Antibody purification method with low isoelectric point
WO2016136933A1 (en) 2015-02-27 2016-09-01 中外製薬株式会社 Composition for treating il-6-related diseases
SG11201709589XA (en) 2015-05-22 2017-12-28 Astellas Pharma Inc NOVEL ANTI-HUMAN NGF ANTIBODY Fab FRAGMENT
JP6897570B2 (en) 2015-12-18 2021-06-30 アステラス製薬株式会社 Anti-human TSLP receptor antibody-containing pharmaceutical composition
KR102546471B1 (en) * 2016-09-27 2023-06-21 프레제니우스 카비 도이치란트 게엠베하 liquid pharmaceutical composition
EP3797792A1 (en) * 2017-03-01 2021-03-31 MedImmune Limited Formulations of anti-gm-csfralpha monoclonal antibody
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to il-6 and neutrophils
JP7235249B2 (en) 2017-10-20 2023-03-08 学校法人兵庫医科大学 Pharmaceutical composition for suppressing postoperative adhesion containing anti-IL-6 receptor antibody
KR20200093628A (en) * 2017-11-30 2020-08-05 바이오-테라 솔루션즈 리미티드 Liquid preparation of humanized antibodies to treat IL-6 related diseases
US20210363238A1 (en) 2018-01-31 2021-11-25 Motokazu Kato Therapeutic agent for asthma containing il-6 inhibitor
US11319375B2 (en) 2018-08-29 2022-05-03 Regeneron Pharmaceuticals, Inc. Methods and compositions for treating subjects having rheumatoid arthritis
CA3128212A1 (en) 2019-01-31 2020-08-06 Sanofi Biotechnology Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis
AU2020255449A1 (en) 2019-03-29 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Anti IL-6 receptor antibody-containing inhibitor for inhibiting deterioration of BBB function
TW202110477A (en) 2019-04-17 2021-03-16 國立大學法人廣島大學 Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
CN115697404A (en) 2020-05-29 2023-02-03 中外制药株式会社 Antibody-containing preparation
KR20220028972A (en) * 2020-08-31 2022-03-08 (주)셀트리온 Stable Pharmaceutical Formulation
KR20230156368A (en) 2021-03-12 2023-11-14 추가이 세이야쿠 가부시키가이샤 Pharmaceutical composition for the treatment or prevention of myasthenia gravis

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20003099A3 (en) * 1998-02-25 2002-04-17 Lexigen Pharmaceuticals Corporation Enhancing the circulating half-life of antibody-based fusion proteins
WO2004039826A1 (en) * 2001-11-14 2004-05-13 Centocor, Inc. Anti-il-6 antibodies, compositions, methods and uses
DK1475101T3 (en) * 2002-02-14 2011-01-10 Chugai Pharmaceutical Co Ltd Antibody-containing pharmaceutical solutions
DE60334141D1 (en) * 2002-10-15 2010-10-21 Facet Biotech Corp CHANGE OF FcRn BINDING SAFFINITIES OR SERUM HALF TIMES OF ANTIBODIES BY MUTAGENESIS
AU2004216298B2 (en) * 2003-02-28 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
CN1798767B (en) * 2003-04-10 2011-02-16 晶面生物技术公司 Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
DE602005020743D1 (en) * 2004-02-11 2010-06-02 Warner Lambert Co PROCESS FOR TREATING OSTEOARTHRITIS WITH ANTI-IL-6 ANTIBODIES
JO3000B1 (en) * 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
EP1977763A4 (en) * 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd Antibody-containing stabilizing preparation
JP2009525986A (en) * 2006-02-03 2009-07-16 メディミューン，エルエルシー Protein preparation
IN2014DN10515A (en) * 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
CA2652976C (en) * 2006-06-02 2015-08-11 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
CA2700701C (en) * 2007-09-26 2020-12-29 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
AR068564A1 (en) * 2007-09-26 2009-11-18 Chugai Pharmaceutical Co Ltd ANTI-RECEIVER ANTIBODY OF IL-6 (INTERLEUQUINA 6)
PL3059246T3 (en) * 2007-09-26 2018-11-30 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
SG189775A1 (en) * 2008-04-11 2013-05-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly

Also Published As

Publication number Publication date
AU2010225951B2 (en) 2014-03-13
JP5661553B2 (en) 2015-01-28
JP2011173918A (en) 2011-09-08
SG174428A1 (en) 2011-10-28
WO2010106812A1 (en) 2010-09-23
KR101468271B1 (en) 2014-12-03
RU2011142184A (en) 2013-04-27
AR075908A1 (en) 2011-05-04
JP4885308B2 (en) 2012-02-29
TWI440470B (en) 2014-06-11
KR20110139745A (en) 2011-12-29
SG10201900451SA (en) 2019-02-27
RU2565809C2 (en) 2015-10-20
AU2010225951A1 (en) 2011-09-22
TW201100100A (en) 2011-01-01
JP2012504106A (en) 2012-02-16

Similar Documents

Publication Publication Date Title
SG10201703707YA (en) Pharmaceutical formulation containing improved antibody molecules
HK1246170A1 (en) Pharmaceutical composition
ZA201006029B (en) Pharmaceutical dosage form
ZA201204266B (en) Antibody formulation
HK1160389A1 (en) Stable liquid antibody formulation
ZA201106503B (en) Antibody formulation
ZA201203242B (en) Antibody formulation
IL225457A0 (en) Pharmaceutical composition
HK1169960A1 (en) Pharmaceutical formulation
GB0810615D0 (en) Novel pharmaceutical
ZA201104348B (en) Pharmaceutical preparation
EP2484697A4 (en) Anti-podoplanin antibody, and pharmaceutical composition containing anti-podoplanin antibody
ZA200903858B (en) Pharmaceutical dosage form
PL394605A1 (en) Stable complex pharmaceutical composition
GB201010453D0 (en) Pharmaceutical composition
GB0815972D0 (en) Pharmaceutical preparation
ZA201207375B (en) Stabilized pharmaceutical composition
EP2306998A4 (en) Pharmaceutical formulation
GB0810617D0 (en) Novel pharmaceutical
GB201001911D0 (en) Pharmaceutical composition
HK1131039A1 (en) Pharmaceutical use of sophoricoside
HK1182939A1 (en) Stable pharmaceutical composition
GB0805292D0 (en) Pharmaceutical formulation
GB0804486D0 (en) Novel pharmaceutical composituons
GB201019775D0 (en) Pharmaceutical composition